| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Chief Financial Officer
5 companies
Coughlin Timothy is a Chief Financial Officer at NEUROCRINE BIOSCIENCES INC with holdings across 5 companies. Recent SEC Form 4 filings include 2 buys and 5 sells.
Estimated insider holdings value: $23.9M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 31, 2025 | TVTX Travere Therapeutics, Inc. | Director | Sale+OE | 18,000 | $35.03 | $630,601.20 | -24.5% | -9.0% | - | |
| May 30, 2024 | ATYR Atyr Pharma Inc | Director | Buy | 50,000 | $1.75 | $87,500.00 | +833.3% | +5.1% | +154.0% | |
| Jun 3, 2022 | FATE Fate Therapeutics Inc | Director | Sell | 1,439 | $22.81 | $32,823.59 | -2.4% | +14.3% | -77.8% | |
| Feb 6, 2017 | NBIX Neurocrine Biosciences Inc | Chief Financial Officer | Sell | 963 | $43.14 | $41,543.82 | -0.7% | - | - | |
| Feb 3, 2017 | NBIX Neurocrine Biosciences Inc | Chief Financial Officer | Sell | 1,500 | $42.55 | $63,825.00 | -1.1% | - | - | |
| Jan 17, 2017 | NBIX Neurocrine Biosciences Inc | Chief Financial Officer | Sell | 1,750 | $40.65 | $71,137.50 | -1.3% | - | - | |
| Nov 23, 2016 | FATE Fate Therapeutics Inc | Director | Buy | 56,390 | $2.66 | $149,997.40 | New | - | - |